» Articles » PMID: 24374889

Are Needle and Syringe Programmes Associated with a Reduction in HIV Transmission Among People Who Inject Drugs: a Systematic Review and Meta-analysis

Overview
Journal Int J Epidemiol
Specialty Public Health
Date 2013 Dec 31
PMID 24374889
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Needle and syringe programmes (NSP) aim to reduce the risk of HIV by providing people who inject drugs (PWID) with sterile injecting equipment. A recent review of reviews (ROR) concluded that there was only tentative evidence to support the effectiveness of NSP in reducing HIV. We carried out a systematic review and meta-analysis to assess the association between NSP and HIV transmission.

Methods: Relevant primary articles presenting data on the risk of HIV transmission associated with NSP were identified in two stages: (i) from reviews identified in two published RORs (covering the period 1980-2008); and (ii) a literature search of CINAHL, Cochrane Library, EMBASE, MEDLINE and PsychINFO for primary articles published since the most recent high quality review (covering the period 2008-12). Study results were synthesized using random-effects meta-analysis.

Results: There were 12 studies comprising at least 12 000 person-years of follow-up. Exposure to NSP was associated with a reduction in HIV transmission: pooled effect size 0·66 [95% confidence interval (CI) 0·43, 1·01] across all studies, and 0·42 (95% CI 0·22, 0·81) across six higher quality studies (according to the Newcastle-Ottawa tool).

Conclusions: There is evidence to support the effectiveness of NSP in reducing the transmission of HIV among PWID, although it is likely that other harm reduction interventions have also contributed to the observed reduction in HIV risk. NSP should be considered as just one component of a programme of interventions to reduce both injecting risk and other types of HIV risk behaviour.

Citing Articles

Perspectives of syringe services program operators in Michigan on their relationship with substance use treatment: a qualitative study.

Reid M, Harris S, Grieb S, Gattine S, Lukco Z, Hool B Harm Reduct J. 2025; 22(1):25.

PMID: 40025510 PMC: 11871840. DOI: 10.1186/s12954-025-01172-5.


Estimating the Cost-Saving Threshold of a Rural Syringe Services Program Before and During the COVID-19 Pandemic.

Allen S, Weir B, Reid M, Schneider K, ORourke A, Hazelett T AIDS Behav. 2025; .

PMID: 39832079 DOI: 10.1007/s10461-025-04615-z.


HIV Prevention in Syringe Service Programs Since the Start of COVID-19: Where Do We Go From Here?.

Hatch M, Ertl M, Closs D, Keeshin S, Feinberg J, Orozco K Curr HIV/AIDS Rep. 2025; 22(1):13.

PMID: 39812953 DOI: 10.1007/s11904-024-00721-0.


"New Normal:" Opportunities and Challenges Faced by Syringe Service Programs Following the Effects of the COVID-19 Pandemic.

Austin E, Briggs E, Corcorran M, Chen J, Cotta N, Behrends C Subst Use Misuse. 2025; 60(5):669-676.

PMID: 39810391 PMC: 11870795. DOI: 10.1080/10826084.2024.2447411.


Correction: Rapid Assessment Amid an Injection Drug Use-Driven HIV Outbreak in Massachusetts' Merrimack Valley: Highlights from a Case Study.

Rapisarda S, Silcox J, Case P, Palacios W, Stopka T, Zaragoza S AIDS Behav. 2024; 29(2):584-588.

PMID: 39676088 PMC: 11813815. DOI: 10.1007/s10461-024-04567-w.